Buruli ulcer lesions in HIV-positive patient

Emerging Infectious Diseases

Volumn 16, Issue 4, 2010, Pages 738-739

  Kibadi, Kapay ^a,b,c   Colebunders, Robert ^a,d   Muyembe Tamfum, Jean Jacques ^b,c   Meyers, Wayne M ^e   Portaels, Françoise ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b Direction of the institute   (Democratic Republic Congo)

^c UNIVERSITY OF KINSHASA   (Congo)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RIFAMPICIN; STREPTOMYCIN;

ADULT; ANTIBIOTIC THERAPY; BACTERIUM CULTURE; BURULI ULCER; CASE REPORT; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LEG ULCER; LETTER; MALE; MYCOBACTERIUM ULCERANS; NONHUMAN; SKIN NODULE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS DETECTION; WOUND DRESSING;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTITUBERCULAR; BURULI ULCER; DRUG THERAPY, COMBINATION; HUMANS; MALE; RIFAMPIN; STREPTOMYCIN;

EID: 77950684634     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1604.091343     Document Type: Letter

References (10)

1. World Health Organization. Buruli ulcer: progress report. Wkly Epidemiol Rec. 2008;83:145-56.
2. Portaels F, Silva MT, Meyers WM. Buruli ulcer. Clin Dermatol. 2009;27:291-305. DOI: 10.1016/j.clindermatol.2008.09.021
3. World Health Organization. Provisional guidance on the role of specifi c antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer) WHO/CDS/CPE/GBUI.10; 2004 [cited 2009 Dec 23]. http://www.who.int/buruli/information/antibiotics/en/index.html
4. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, Phillips R, et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother. 2005;49:3182-6. DOI: 10.1128/AAC.49.8.3182-3186.2005
5. Kibadi K, Panda M, Tamfum JJ, Fraga AG, Longatto Filho A, Anyo G, et al. New foci of Buruli ulcer, Angola and Democratic Republic of Congo. Emerg Infect Dis. 2008;14:1790-2. DOI: 10.3201/eid1411.071649
6. Kibadi K. Mycobacterium ulcerans disease (Buruli ulcer): surgical treatment of 102 cases in the Democratic Republic of Congo [in French]. Med Trop (Mars). 2005;65:444-8.
7. Eddyani M, Debacker M, Martin A, Aguiar J, Johnson CR, Uwizeye C, et al. Primary culture of Mycobacterium ulcerans from human tissue specimens after storage in semi-solid transport medium. J Clin Microbiol. 2008;46:69-72. DOI: 10.1128/JCM.00301-07
8. Johnson RC, Nackers F, Glynn JR, de Biurrun Bakedano E, Zinsou C, Aguiar J, et al. Association of HIV infection and Mycobacterium ulcerans disease in Benin. AIDS. 2008;22:901-3. DOI: 10.1097/QAD.0b013e3282f7690a
9. Chauty A, Ardant MF, Adeye A, Euverte H, Guédénon A, Johnson C, et al. Promising clinical effi cacy of streptomycinrifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother. 2007;51:4029-35. DOI: 10.1128/AAC.00175-07
10. Toll A, Gallardo F, Ferran M, Gilaberte M, Iglesias M, Gimeno JL, et al. Aggressive multifocal Buruli ulcer with associated osteomyelitis in an HIV-positive patient. Clin Exp Dermatol. 2005;30:649-51. DOI: 10.1111/j.1365-2230.2005.01892.x